天邦食品(002124) - 2019 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2019 was ¥1,245,086,754.50, representing a 47.64% increase compared to ¥843,300,297.75 in the same period last year[10] - The net profit attributable to shareholders was -¥335,287,082.36, a decrease of 1,141.95% from ¥32,178,832.76 in the previous year[10] - Basic and diluted earnings per share were both -¥0.29, down 825.00% from ¥0.04 in the previous year[10] - The weighted average return on equity was -15.15%, a decrease of 16.21% from 1.06% in the same period last year[10] - The company reported a net loss of ¥147,548,574.00 in retained earnings, compared to a profit of ¥187,738,508.36 in the previous period[44] - The total revenue for the current period is CNY 81,702,639.24, a decrease of 3.4% compared to CNY 84,610,616.91 in the previous period[60] - The net profit for the current period is CNY -336,196,101.91, compared to a net profit of CNY 31,294,234.15 in the previous period, indicating a significant decline[59] - The operating profit for the current period is CNY -271,516,088.91, down from CNY 37,144,195.85 in the previous period[59] - The comprehensive income total for the current period is CNY -337,129,612.05, compared to CNY 29,176,974.69 in the previous period[59] - The total profit for the current period is CNY -335,255,206.42, compared to CNY 35,240,916.64 in the previous period, reflecting a substantial loss[59] Cash Flow - The net cash flow from operating activities was -¥44,905,739.77, a decline of 3,110.10% compared to ¥1,491,835.53 in the same period last year[10] - Cash inflow from financing activities was CNY 1,130,043,333.33, significantly higher than CNY 682,000,000.00 in the previous period, driven by increased borrowings[73] - Cash outflow for debt repayment was CNY 784,502,666.34, a substantial increase from CNY 94,000,000.00, reflecting a strategic focus on reducing leverage[73] - Operating cash inflow totaled CNY 1,437,616,179.32, compared to CNY 955,853,388.72 in the previous period, reflecting a significant increase[70] - Operating cash outflow amounted to CNY 1,482,521,919.09, up from CNY 954,361,553.19, leading to a net cash flow from operating activities of CNY -44,905,739.77, a decline from CNY 1,491,835.53[70] - The total cash and cash equivalents at the end of the period were CNY 468,353,460.96, compared to CNY 586,244,275.17 in the previous period, showing a decrease[73] - The net increase in cash and cash equivalents was CNY 36,443,381.14, a decrease from CNY 168,462,741.68 in the previous period, highlighting tighter liquidity conditions[73] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,174,409,586.88, a decrease of 0.87% from ¥6,228,766,400.88 at the end of the previous year[10] - Total liabilities amounted to 4,114,325,759.70 yuan as of March 31, 2019[38] - The total equity attributable to shareholders was ¥2,254,836,348.25, down from ¥2,288,899,216.69, indicating a decrease of 1.5%[51] - The total liabilities were ¥2,259,676,727.54, an increase of 9.0% from ¥2,073,664,500.63 year-on-year[48] - The company’s total liabilities and equity amounted to ¥6,174,409,586.88, a slight decrease from ¥6,228,766,400.88[44] Operating Costs and Expenses - Operating costs increased by 93.5% year-on-year, attributed to the increase in sales volume[22] - Research and development expenses increased by 38% year-on-year, mainly due to increased direct investment in R&D[22] - Financial expenses increased by 382% year-on-year, primarily due to an increase in loan amounts[22] - The company recognized a loss of ¥65,890,966.68 from the disposal of non-current assets due to upgrades and scrapping of old assets during the reporting period[10] - The company reported a 76.2% decrease in income tax expenses year-on-year, mainly due to a decline in pre-tax profit from vaccine sales[22] - Research and development expenses were ¥23,339,844.71, representing a 38.0% increase from ¥16,912,315.63 in the previous year[52] - The research and development expenses for the current period are CNY 5,679,038.33, slightly down from CNY 5,941,906.69 in the previous period[60] - The financial expenses for the current period are CNY 20,508,986.64, significantly higher than CNY 6,164,094.45 in the previous period, primarily due to increased interest expenses[60] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,129[14] - The net assets attributable to shareholders decreased by 14.11% to ¥2,044,574,434.41 from ¥2,380,518,922.26 at the end of the previous year[10] Government Subsidies - The company received government subsidies amounting to ¥10,620,437.90 during the reporting period[10] - Other income increased by 987.8% year-on-year, mainly due to an increase in government subsidies received[22] Audit Information - The company did not undergo an audit for the first quarter report, which may affect the reliability of the financial data presented[80]